MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S. Center...

1. CMS Approves Add-on Payment for Lutonix® Drug-Coated
Balloon for Inpatient Use
MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S.
Centers for
Medicare and Medicaid Services (CMS) has approved a new technology
add-on payment for the Lutonix® Drug-Coated Balloon (DCB)
under the Medicare hospital inpatient prospective payment system. The
purpose of the reimbursement is to help cover additional cost to U.S.
hospitals for treating Medicare beneficiaries with the Lutonix®
DCB in the inpatient setting. CMS determined the amount of the add-on
payment to be a maximum of $1,036 when DCBs are used for inpatient
peripheral procedures and the total device costs exceed the allowance
for existing DRG reimbursement. The add-on payment is effective October
1, 2015.
The Lutonix® 035 DCB--the first FDA-approved
DCB-- is an
angioplasty balloon coated with a therapeutic
dose of the drug
paclitaxel, and also utilizes standard mechanical
dilatation of the
vessel to restore blood flow for patients with
peripheral arterial
disease (PAD) in the femoropopliteal arteries.
Timothy M. Ring, chairman and chief executive
officer, commented, "After
providing reimbursement in the outpatient setting earlier this year, CMS
has now provided additional reimbursement for the Lutonix®

2. DCB in the inpatient setting, which demonstrates the benefit to patients
from this breakthrough technology."
C. R. Bard, Inc. (www.crbard.com),
headquartered in Murray Hill, N.J., is a leading multinational
developer, manufacturer and marketer of innovative, life-enhancing
medical technologies in the fields of vascular, urology, oncology and
surgical specialty products.
This press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management's current expectations, the accuracy of which is
necessarily subject to risks and uncertainties. These statements are not
historical in nature and use words such as "anticipate", "estimate",
"expect", "project", "intend", "forecast", "plan", "believe", and other
words of similar meaning in connection with any discussion of future
operating or financial performance. Many factors may cause actual
results to differ materially from anticipated results including product
developments, sales efforts, income tax matters, the outcomes of
contingencies such as legal proceedings, and other economic, business,
competitive and regulatory factors. The company undertakes no obligation
to update its forward-looking statements. Please refer to the Cautionary
Statement Regarding Forward-Looking Information in our June 30, 2015
Form 10-Q for more detailed information about these and other factors
that may cause actual results to differ materially from those expressed
or implied.
http://www.businesswire.com/news/home/20150803005392/en/CMS-Approves-Add-on-Payment-Luto

3. nix%C2%AE-Drug-Coated-Balloon